mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are
Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
Dual-Use Ventures & Intellectual Property: SBIR Data Rights, Patents, and Deals
Dual-use ventures—startups that intend to sell both commercially and to the Department of Defense (DoD)—enjoy many advantages. You have a
Continue Reading Dual-Use Ventures & Intellectual Property: SBIR Data Rights, Patents, and Deals
Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums
Continue Reading Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
A Framework for Protecting Your Invention Outside the U.S.
Patent protection outside the U.S. can be important for a company to enter the global market and to build relationships
Continue Reading A Framework for Protecting Your Invention Outside the U.S.
Pitfalls of Attorney-Client Privilege and Tips for Corporate Officers and Employees
Elizabeth Holmes, former CEO of the now-defunct blood-testing technology company Theranos, recently learned a harsh lesson on the complexities and
Continue Reading Pitfalls of Attorney-Client Privilege and Tips for Corporate Officers and Employees
The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital
Continue Reading Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
Key Takeaways from Google’s Supreme Court Copyright Win Over Oracle
The Supreme Court’s recent landmark ruling in Google v. Oracle ended a decade-long legal battle between the tech giants, finding
Continue Reading Key Takeaways from Google’s Supreme Court Copyright Win Over Oracle